Skip to main content
Figure 4 | BMC Pharmacology and Toxicology

Figure 4

From: Preclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen®

Figure 4

Mean neutrophil counts (× 10 3 /μl) ± SD measured in human healthy volonteers treated for 7 days by subcutaneous injections of BK0023 (triangles) and Neupogen ®  (circles) at dosage of 2.5 μg/kg/day (upper panel) and 5.0 μg/kg/day (central panel) and for 5 days by subcutaneous injections of BK0023 and Neupogen ®  at dosage of 10.0 μg/kg/day (lower panel).

Back to article page